Cargando…

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer

Identification of ROS1 rearrangements in patients with lung cancer allows them to benefit from targeted therapy. We compared immunohistochemistry (IHC) with more cumbersome methods such as fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for identification of RO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyle, Theresa A., Masago, Katsuhiro, Ellison, Kim E., Yatabe, Yasushi, Hirsch, Fred R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770803/ https://www.ncbi.nlm.nih.gov/pubmed/25467930 http://dx.doi.org/10.1016/j.cllc.2014.10.003

Ejemplares similares

Biopsy of palliative lesions following radiotherapy
por: Fujita, Shiro, et al.
Publicado: (2019)

Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer
por: Fujita, Shiro, et al.
Publicado: (2021)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
por: Nishimatsu, Kanako, et al.
Publicado: (2023)

The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
por: Shinohara, Shuichi, et al.
Publicado: (2023)

Comparison of Different ROS1 Immunohistochemistry Clones and Consistency with Fluorescence In Situ Hybridization Results in Non-Small Cell Lung Carcinoma
por: Dülger, Onur, et al.
Publicado: (2023)

Is Primary Pulmonary Meningioma a Giant Form of a Meningothelial-Like Nodule? A Case Report and Review of the Literature
por: Masago, Katsuhiro, et al.
Publicado: (2012)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment
por: Masago, Katsuhiro, et al.
Publicado: (2022)

Targeted RNA sequencing with touch imprint cytology samples for non‐small cell lung cancer patients
por: Seto, Katsutoshi, et al.
Publicado: (2020)

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma
por: Grenier, Karl, et al.
Publicado: (2023)

Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer
por: Fujita, Shiro, et al.
Publicado: (2015)

Clinical significance of Girdin expression detected by immunohistochemistry in non-small cell lung cancer
por: SONG, JING-YING, et al.
Publicado: (2014)

Clinical potential of necitumumab in non-small cell lung carcinoma
por: Genova, Carlo, et al.
Publicado: (2016)

Clinical Guideline-Guided Outcome Consistency for Surgically Resected Stage III Non-Small Cell Lung Cancer: A Retrospective Study
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2017)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
por: Lee, Jongmin, et al.
Publicado: (2018)

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
por: Fujita, Shiro, et al.
Publicado: (2012)

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
por: Masago, Katsuhiro, et al.
Publicado: (2015)

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer
por: Zhang, Liping, et al.
Publicado: (2015)

Visualization of patterns of lymph node metastases in non–small cell lung cancer using network analysis
por: Yoshida, Yukihiro, et al.
Publicado: (2022)

Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer
por: Gkika, Eleni, et al.
Publicado: (2020)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
por: Rakaee, Mehrdad, et al.
Publicado: (2019)

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Togashi, Yosuke, et al.
Publicado: (2011)

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)
por: Shimizu, Junichi, et al.
Publicado: (2020)

Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
por: Fujita, Shiro, et al.
Publicado: (2010)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer
por: Kagawa, Yusuke, et al.
Publicado: (2020)

Loss of STING expression is prognostic in non–small cell lung cancer
por: Lohinai, Zoltan, et al.
Publicado: (2022)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
por: Mraihi, Zohra, et al.
Publicado: (2018)

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review
por: Koomen, Bregje M, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer
por: Hofman, Véronique, et al.
Publicado: (2023)

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
por: Oya, Yuko, et al.
Publicado: (2017)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i76b2h28fotra58ri2cn26bo96